GC203 yog ib txoj kev kho mob TIL tshiab uas tsis yog kab mob uas hloov kho los ntawm cov noob caj noob ces uas tau tsim los ntawm kev siv Juncell Therapeutics lub platform nthuav dav DeepTIL® thiab NovaGMP® gene modification platform. DeepTIL® ua rau TILs muaj zog txaus uas tsis tas yuav muaj kev sib xyaw ua ke IL-2 tom qab txhaj tshuaj, thiab qhov muaj zog ntawm kev kho ua ntej yuav qis dua. NovaGMP® hloov kho T cell nrog kev ua haujlwm zoo sib xws nrog Lentiviral vector hauv txoj kev pheej yig. GC203 tau tsim nrog tus kheej-associating membrane-bound interleukin-7, uas tuaj yeem tswj tau qhov stemness ntawm cov cim xeeb T cell, ua kom cov hlwb tiv thaiv kab mob sab hauv thiab zam kev lom neeg hauv lub cev.
Cov kws tshawb fawb tau sim GC203 rau cov neeg mob uas kuaj pom tias muaj mob qog nqaij hlav zes qe menyuam rov qab los, yam tsis muaj kev sib xyaw ua ke ntawm IL-2 kev tswj hwm lossis kev tawm dag zog lymphodepletion. Lub hom phiaj ntawm txoj kev tshawb fawb no yog txhawm rau txiav txim siab qhov kev nyab xeeb thiab kev ua haujlwm ntawm kev kho mob no. Tag nrho ntawm 20 tus neeg mob tau sau npe ntawm 09/2021 thiab 01/2024 hauv kev sim qhib-daim ntawv lo ib lub chaw, uas 18 tus neeg mob tau raug soj ntsuam. Cov neeg mob uas tau soj ntsuam yog nrog ECOG PS ntawm 1 (55.6%) lossis 2 (44.4%) thiab tau txais qhov nruab nrab ntawm 5 kev kho mob yav dhau los (ntau yam: 2-11). 9 (50%) cov neeg mob muaj 3 lossis ntau dua qhov mob qog. Qhov nruab nrab ntawm qhov mob qog yog 57 (ntau yam: 13-146) hli.
GC203 tau qhia txog cov txiaj ntsig zoo rau cov neeg mob uas muaj mob qog nqaij hlav zes qe menyuam rov qab los yog kis mus rau lwm qhov. Cov ntaub ntawv kev nyab xeeb tau zoo dua piv rau cov kev kho mob TIL ib txwm muaj, ua tsaug rau kev kho mob ua ntej uas tsis muaj zog thiab kev tshem tawm IL-2 ua ke. Feem ntau ntawm Cov Xwm Txheej Tsis Zoo (AEs) yog qib 1 lossis qib 2 thiab tuaj yeem txo qis lossis kho tau los ntawm kev kho mob tsos mob. Tsis muaj qib 5 tshwm sim. Los ntawm hnub kawg ntawm 01/2024, tus kws tshawb nrhiav tau soj ntsuam Tus Nqi Teb Rov Qab (ORR) yog 33.3% (95% CI: 16.3 - 56.3), suav nrog 11.1% Kev Teb Rov Qab Tag Nrho (CR). Tus Nqi Tswj Kab Mob (DCR) yog 83.3% (95% CI, 60.8 - 94.2). Thiab 12-hli Tag Nrho Kev Ciaj Sia (OS) tus nqi yog 68.8% (95% CI: 49.3 - 95.9). Tus OS nruab nrab tsis tau loj hlob raws li cov ntaub ntawv txiav tawm.
Xyoo 2023, Ms. H tau raug xa mus rau tsev kho mob xyoo 2023 vim yog mob qhov chaw mos.thiab mob duavThaum kuaj xyuas, pom tias muaj ntau lub qog ntshav hauv qhov chaw retroperitoneum, qhov chaw mos, thiab lwm qhov chaw, ua pov thawj tias nws muaj mob qog ntshav hauv zes qe menyuam. Yog li Ms. H tau txais kev kho mob chemotherapy, phais, tshuaj tiv thaiv kab mob, thiab lwm yam, tab sis qhov tshwm sim tsis zoo, thiab qhov mob qog rov tshwm sim dua.
Yog li ntawd, Ms. H tau koom nrog kev sim tshuaj ntawm TIL cell therapy GC203, thiab tom qab ib hlis ntawm kev kho mob nrog GC203, qhov mob qog nqaij hlav tau me me los ntawm 37.3%.
Xaus Lus: Kev txhaj tshuaj GC203muaj kev nyab xeeb thiab ua tau zoo rau cov neeg mob OC rov qab los uas muaj kev xaiv kho mob tsawg.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Cov ntaub ntawv siv los ua piv txwv
1.https://www.juncell.com/academic-achieves
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Lub sijhawm tshaj tawm: Lub Kaum Ob Hlis-11-2024